Skip to content
DraconiticResearch
Search Sources API
194,220 studies31 sourcesUpdated 41 min ago
Peer-reviewedCC BY 4.0Journal of Analytical Methods in Chemistry

Study on the Active Constituents and Underlying Mechanisms of Renshen Yangying Decoction Against Angina Pectoris Based on Integrated Serum Pharmacochemistry, Network Pharmacology, Molecular Docking, and Experimental Validation

  • Ya Huang1,2
  • Tao Xiong2
  • Haixia Qiu2
  • Rui Cheng2
  • Yule Luo2
  • Xingdong Wu1,2
  1. 1Jinsha County Chinese Medicine Hospital Jinsha Guizhou 551800 China
  2. 2School of Pharmacy Zunyi Medical University Zunyi Guizhou 563000 China zmc.edu.cn
Read full textPDFDOICite

Abstract

Objective: This study aims to elucidate the pharmacological basis and underlying molecular mechanisms of Renshen Yangying decoction (RYD) in alleviating angina pectoris.

Methods: UHPLC–Q‐TOF‐MS was used to profile chemical constituents in RYD and RYD‐medicated serum. Compound identification was performed using a custom database, literature, reference standards, and the GNPS platform. Network pharmacology predicted disease‐related targets and pathways, followed by molecular docking and in vitro AC16 cardiomyocyte assays for validation.

Results: A total of 179 constituents in the decoction and 37 absorbed prototype compounds (mainly flavonoids, organic acids, alkaloids, and coumarins) were identified. 282 shared targets with angina were obtained, yielding 10 core targets (e.g., AKT1, TNF, BCL2, STAT3, and EGFR). Four main compounds (naringenin, schisantherin B, schisandrol A, and quercetin) were predicted to modulate EGFR, IGF‐1R, and PDGFR‐β pathways. Naringenin was experimentally confirmed to alleviate pathological damage by suppressing inflammatory responses.

Conclusion: RYD exerts antiangina effects through a multicomponent, multitarget, multipathway mechanism involving EGFR, PI3K–Akt, and PDGFR‐β signaling, with naringenin, schisantherin B, schisandrol A, and quercetin as major active constituents. These findings provide mechanistic insights supporting the clinical application of RYD.

Related

  1. Unraveling the multitarget mechanisms of aloe emodin against periodontitis: a synergy of network pharmacology and experimental validation
    Yifan Zhang, Huijing Ma, Shengxiang Zhang +5
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossrefEurope PMCPMC
  2. Unraveling the therapeutic mechanisms of placenta hominis for polycystic ovary syndrome through network pharmacology, molecular docking, and experimental validation
    Haixia Pan, Meilin Wu, Ting Mao +7
    Scientific ReportsPeer-reviewedCC BYFull textObstetrics, gynaecology & paediatricsDOAJ
  3. Network pharmacology and experimental validation reveal the anti-inflammatory mechanisms of andrographolide in the treatment of periodontitis.
    Xia Chen, Yu Luo, Xiaoyan Zou +3
    BMC oral healthPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMCDOAJ
  4. Chinese herbal medicine for recurrent urinary tract infection: formulation-specific clinical evidence, experimental pharmacology, and unresolved recurrence mechanisms
    Pengtian Zhang, Xuming Zhang, Chaoyue Ji +1
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textEpidemiology & public healthCrossrefDOAJ
  5. Exploring the potential mechanisms of Pei Yuan Yi Fei decoction for non-small cell lung cancer through network pharmacology and experimental validation
    Yingjia Zhou, Jia Wu, Mei Li +5
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMCPMCEurope PMC

Cite

BibTeXRIS
BibTeX
@article{huang2026study,
  title = {{Study on the Active Constituents and Underlying Mechanisms of Renshen Yangying Decoction Against Angina Pectoris Based on Integrated Serum Pharmacochemistry, Network Pharmacology, Molecular Docking, and Experimental Validation}},
  author = {Ya Huang and Tao Xiong and Haixia Qiu and Rui Cheng and Yule Luo and Xingdong Wu},
  journal = {Journal of Analytical Methods in Chemistry},
  year = {2026},
  month = nov,
  doi = {10.1155/jamc/6325730},
  url = {https://doi.org/10.1155/jamc/6325730},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Study on the Active Constituents and Underlying Mechanisms of Renshen Yangying Decoction Against Angina Pectoris Based on Integrated Serum Pharmacochemistry, Network Pharmacology, Molecular Docking, and Experimental Validation
AU  - Ya Huang
AU  - Tao Xiong
AU  - Haixia Qiu
AU  - Rui Cheng
AU  - Yule Luo
AU  - Xingdong Wu
PY  - 2026
DA  - 2026/11/03
JO  - Journal of Analytical Methods in Chemistry
DO  - 10.1155/jamc/6325730
UR  - https://doi.org/10.1155/jamc/6325730
AB  - Objective: This study aims to elucidate the pharmacological basis and underlying molecular mechanisms of Renshen Yangying decoction (RYD) in alleviating angina pectoris.  Methods: UHPLC–Q‐TOF‐MS was used to profile chemical constituents in RYD and RYD‐medicated serum. Compound identification was performed using a custom database, literature, reference standards, and the GNPS platform. Network pharmacology predicted disease‐related targets and pathways, followed by molecular docking and in vitro AC16 cardiomyocyte assays for validation.  Results: A total of 179 constituents in the decoction and 37 absorbed prototype compounds (mainly flavonoids, organic acids, alkaloids, and coumarins) were identified. 282 shared targets with angina were obtained, yielding 10 core targets (e.g., AKT1, TNF, BCL2, STAT3, and EGFR). Four main compounds (naringenin, schisantherin B, schisandrol A, and quercetin) were predicted to modulate EGFR, IGF‐1R, and PDGFR‐β pathways. Naringenin was experimentally confirmed to alleviate pathological damage by suppressing inflammatory responses.  Conclusion: RYD exerts antiangina effects through a multicomponent, multitarget, multipathway mechanism involving EGFR, PI3K–Akt, and PDGFR‐β signaling, with naringenin, schisantherin B, schisandrol A, and quercetin as major active constituents. These findings provide mechanistic insights supporting the clinical application of RYD.
SN  - 2090-8865
SN  - 2090-8873
ER  -